125481-61-0Relevant articles and documents
Development and scale-up of three consecutive continuous reactions for production of 6-hydroxybuspirone
LaPorte, Thomas L.,Hamedi, Mourad,DePue, Jeffrey S.,Shen, Lifen,Watson, Daniel,Hsieh, Daniel
, p. 956 - 966 (2008)
This paper describes the development of a continuous, high yielding, and scalable enolization, oxidation, and quench process for the hydroxylation of the azapirone psychtropic agent buspirone to afford 6-hydroxybuspirone (6-hydroxy-8-[4-(4-pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5] decane-7,9-dione). Two feed streams were reacted continuously using an in-line static mixer followed by oxidation in a continuous flow trickle-bed reactor. The laboratory reactor operation was demonstrated at steady state for over 40 h. The process was scaled up using both volumetric (enolization) and numbering-up (oxidation) scale-up strategies. A pilot-plant reactor was developed and successfully implemented in a three-batch campaign (47 kg input per batch).
CONTINUOUS PROCESS FOR PRODUCING HYDROXYAZAPIRONES BY OXIDATION
-
Page/Page column 17-18, (2008/06/13)
A method for continuous production of hydroxyazapirones, for example 6-hydroxybuspirone, using a modified reactor. The products of the invention are useful as pharmaceutical agents.
Development of a safe and scalable oxidation process for the preparation of 6-hydroxybuspirone: Application of in-line monitoring for process ruggedness and product quality
Watson, Daniel J.,Dowdy, Eric D.,DePue, Jeffrey S.,Kotnis, Atul S.,Leung, Simon,O'Reilly, Brian C.
, p. 616 - 623 (2013/09/02)
The development of a safe and scalable oxidation process for the hydroxylation of the azapirone psychotropic agent buspirone (1) to furnish 6-hydroxybuspirone (2) is described. A mechanistic understanding of how key process factors affected product quality led to the successful application of FTIR as a process analytical technology (PAT) tool. This enabled real time quality assurance and the development of an effective and efficient manufacturing process. The identification of impurities and the development of recrystallization methods to provide active pharmaceutical ingredients (API) with optimal purity will also be addressed.